The large scale adoption of prefilled syringes demonstrated the growing interest in the concept of such convenient drug delivery systems. Large volume wearable injectors are advanced versions of the existing self-injection devices. The ‘Large Volume Wearable Injectors Market (3rd Edition), 2017-2027′ report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years.
The Market Landscape is Steadily Widening
With a fast growing biologics pipeline, several companies have taken initiatives to develop large volume self injection devices to address the growing unmet need
Start-Ups / Small Companies Are Consistently Fostering Innovation
Device developers have continuously driven more innovation; this is reflected by the presence of a variety of novel features in the devices being investigated
Reusable Injectors are Dominating the Market
Reusable devices offer a more cost-efficient solution to end-users who are required to take medication for chronic indications such as diabetes
Insulin Delivery to Diabetics is the Current Focus …
With integration of glucose monitoring systems, the devices for insulin delivery have gained more attention; this is clearly reflected by the rising popularity on social media portals
… However, a Number of Non-Insulin Delivery Devices are Likely to Emerge
There are very few devices approved for delivery of non-insulin biologics; the success of these devices is likely to provide an impetus to the overall market
The Technology is Expected to Revolutionize the Well-Established Drug Delivery Market
The overall market is poised to grow at annualized rate of close to 100% as a number of drug-device combinations are expected to get approved in the coming decade
Several Biologics, Across Multiple Indications, Will Drive the Long Term Growth\
Our analysis suggests that close to 100 biologics (marketed / under development) are suited for delivery via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. These biologics (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems. We believe that some of these drugs, if tested and approved with large volume wearable injectors, are likely to make a substantial contribution to the market’s evolution in the mid-long term.
To know more please click here. For any queries / suggestions or if you’d like to get access to the full research results, please do not hesitate to contact us at firstname.lastname@example.org.